Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Eyassu Chernet"'
Autor:
Richard G Conway, Eyassu Chernet, David C De Rosa, Robert J Benschop, Anne B Need, Emily C Collins, James S Bean, J Michael Kalbfleisch, Mark D Rekhter
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e50349 (2012)
(18)F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging of atherosclerosis in the clinic is based on preferential accumulation of radioactive glucose analog in atherosclerotic plaques. FDG-PET is challenging in mouse models due to l
Externí odkaz:
https://doaj.org/article/f41871f555ec4207b4e3c75e279b22fc
Autor:
Mario Rossi, R. A. John Challiss, Colin Molloy, Eyassu Chernet, Sophie J. Bradley, Paulina Valuskova, Lisa M. Broad, Adrian J. Mogg, Karolina Gherbi, Vanessa N. Barth, Elizabeth M. Rosethorne, Andrew B. Tobin, Arthur Christopoulos, Caroline A. Wilson, Lisa Finlayson, Louis Dwomoh, Miriam Scarpa, Rajendra Mistry, Shuzo Sakata, Patrick M. Sexton, Kjell A. Svensson, David A. Sykes
Cholinesterase inhibitors, the current frontline symptomatic treatment for Alzheimer’s disease (AD), are associated with low efficacy and adverse effects. M1 muscarinic acetylcholine receptors (M1 mAChRs) represent a potential alternate therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e98a59cb796f11c7703f6b34d2e88b3
https://strathprints.strath.ac.uk/71527/1/Bradley_etal_NCB_2019_Biased_M1_muscarinic_receptor_mutant_mice_inform.pdf
https://strathprints.strath.ac.uk/71527/1/Bradley_etal_NCB_2019_Biased_M1_muscarinic_receptor_mutant_mice_inform.pdf
Autor:
Jayne A. Talbot, Raymond F. Biondolillo, John E. Buckholz, Barry A Jones, Jon P. Butler, Barry S. Lutzke, Kjell A. Svensson, Eyassu Chernet, Jennifer M Cox, Bradley L. Ackermann
Publikováno v:
Bioanalysis. 7:2461-2475
Background: Human cerebrospinal fluid (CSF) is often acquired in Phase I clinical trials to assess the CNS penetration of new pharmacological agents and to search for biomarkers associated with PD effects. Robust methods for neurotransmitter metaboli
Autor:
Michelle M Menezes, Jeffrey M. Witkin, Kjell A. Svensson, Brian J. Eastwood, Eyassu Chernet, Michael J. O'Neill, Julie F. Falcone, Keith A. Wafford, Hong Wang, Linda K. Thompson, John W. Ryder, Stephen N. Mitchell, Junliang Hao, John Mehnert Schaus, Robert F. Bruns, Alex J. Harper, Meghane E. Masquelin, Deanna L Maren, Xia Li, Tracey K. Murray, Charles R. Yang, Elaine Shanks, Jason Katner, Linli Zhang, Guy Carter, James P. Beck, Patrick L. Love
Publikováno v:
Neuropharmacology. 128
DETQ, an allosteric potentiator of the dopamine D1 receptor, was tested in therapeutic models that were known to respond to D1 agonists. Because of a species difference in affinity for DETQ, all rodent experiments used transgenic mice expressing the
Autor:
Xiyun Chai, Jason S. Katber, Eyassu Chernet, Theresa A. Day, Su Wu, Mansuo L. Hayashi, Francis David Tingley, Kjell A. Svensson
Publikováno v:
Alzheimer's & Dementia. 12
Autor:
Amy K. Chesterfield, Christian C. Felder, Sean R. Donohue, Lee A. Phebus, Joseph Herman Junio Krushinski, Christer Halldin, Victor W. Pike, Eyassu Chernet, John M. Schaus
Publikováno v:
Journal of Medicinal Chemistry. 51:5833-5842
We have reported that [methyl-11C] (3R,5R)-5-(3-methoxyphenyl)-3-[(R)-1-phenylethylamino]-1-(4-trifluoromethylphenyl)pyrrolidin-2-one ([11C]8, [11C]MePPEP) binds with high selectivity to cannabinoid type-1 (CB1) receptors in monkey brain in vivo. We
Autor:
Sami S. Zoghbi, Christer Halldin, Johannes Tauscher, Lee A. Phebus, Garth E. Terry, Robert B. Innis, Victor W. Pike, John Mehnert Schaus, Jeih-San Liow, Eyassu Chernet, Christian C. Felder
Publikováno v:
NeuroImage. 41:690-698
[11C]MePPEP is an inverse agonist and a radioligand developed to image cannabinoid CB1 receptors with positron emission tomography (PET). It provides reversible, high specific signal in monkey brain. We assessed [11C]MePPEP in rodent brain with regar
Autor:
Gardinier Kevin Matthew, Stephen A. Hitchcock, John Mehnert Schaus, Victor W. Pike, Jinsoo Hong, Christer Halldin, Kevin Michael Ruley, Eyassu Chernet, Joseph H. Krushinski, Magnus Schou, Lee A. Phebus, Sean R. Donohue
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 51:146-152
PipISB [N-(4-fluoro-benzyl)-4-(3-(piperidin-1-yl)-indole-1-sulfonyl)benzamide, 9] was identified as a selective high potency CB1 receptor ligand. Here we describe the labeling of 9 with positron-emitters to provide candidate radioligands for imaging
Autor:
Laura J. Martin, Eyassu Chernet, Anne B. Need, Lee A. Phebus, Michelle Morin, Karen S. Rash, Vanessa N. Barth
Publikováno v:
Life Sciences. 78:3007-3012
Preclinical brain receptor occupancy measures have heretofore been conducted by quantifying the brain distribution of a radiolabeled tracer ligand using either scintillation spectroscopy or tomographic imaging. For smaller animals like rodents, the m
Autor:
Vanessa N. Barth, Laura J. Martin, Karen S. Rash, Eyassu Chernet, Dominic L. Li, Lee A. Phebus, Anne B. Need
Publikováno v:
Life Sciences. 78:340-346
High performance liquid chromatography combined with either single quad or triple quad mass spectral detectors (LC/MS) was used to measure the brain distribution of receptor occupancy tracers targeting dopamine D2, serotonin 5-HT2A and neurokinin NK-